Theis Aagaard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Theis Aagaard has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Gedske Daugaard
Department of Oncology Rigshospitalet University of Copenhagen Copenhagen Denmark
5 shared publicationsHenrik Sengeløv
Department of Haematology Rigshospitalet University of Copenhagen Copenhagen Denmark
5 shared publicationsJens Lundgren
Centre of Excellence for Health, Immunity and Infections (CHIP) Rigshospitalet University of Copenhagen Copenhagen Denmark
5 shared publicationsAmanda Mocroft
Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME) Institute for Global Health University College London London UK
4 shared publicationsAshley Roen
Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME) Institute for Global Health University College London London UK
4 shared publicationsJoanne Reekie
Centre of Excellence for Health, Immunity and Infections (CHIP) Rigshospitalet University of Copenhagen Copenhagen Denmark
3 shared publications
Latest Publications
- Open Access
- 7 March 2020
- Published by Wiley in Cancer Medicine
- Vol. 9 (9) , 3033-3042
Mortality and admission to intensive care units after febrile neutropenia in patients with cancer
Febrile neutropenia (FN) is a critical complication of chemotherapy associated with increased in‐hospital mortality. However, associations with increased mortality and intensive care unit (ICU) admissions during longer follow‐up are not established. Patients treated with standard first‐line chemotherapy for solid cancers at Rigshospitalet, Denmark in 2010‐2016 were included. Incidence rate ratios (IRR) of all‐cause, infectious and cardiovascular mortality, and ICU admissions after FN were analyzed by Poisson regression. Risk factors at the time of FN were analyzed in the subpopulation of patients with FN; all‐cause mortality was further stratified by the time periods 0‐30, 31‐365, and 366+ days after FN. We included 9018 patients with gastric (14.4%) and breast (13.1%) cancer being the most common, 51.2% had locally advanced or disseminated disease and the patients had a median Charlson Comorbidity Index score of 0 (interquartile range, 0‐0). During follow‐up, 845 (9.4%) experienced FN and 4483 (49.7%) died during 18 775 person‐years of follow‐up. After adjustment, FN was associated with increased risk of all‐cause mortality, infectious mortality, and ICU admissions with IRRs of 1.39 (95% CI, 1.24‐1.56), 1.94 (95% CI, 1.43‐2.62), and 2.28 (95% CI, 1.60‐3.24). Among those with FN, having a positive blood culture and low lymphocytes were associated with excess risk of death and ICU admissions (predominantly the first 30 days after FN), while elevated C‐reactive protein and low hemoglobin predicted mortality the first year after FN. The risk of death varied according to the time since FN; adjusted IRR per additional risk factor present for the time periods 0‐30, 31‐365, and 366+ days after FN were 2.00 (95% CI, 1.45‐2.75), 1.36 (95% CI, 1.17‐1.57), and 1.17 (95% CI, 0.98‐1.41). FN was associated with increased mortality and risk of ICU admissions. An objectively identifiable subgroup of patients among those with FN carried this excess risk.
- 7 March 2020
- Published by Wiley in Cancer Medicine
- Vol. 9 (9) , 3033-3042
Open AccessMortality and admission to intensive care units after febrile neutropenia in patients with cancer
Febrile neutropenia (FN) is a critical complication of chemotherapy associated with increased in‐hospital mortality. However, associations with increased mortality and intensive care unit (ICU) admissions during longer follow‐up are not established. Patients treated with standard first‐line chemotherapy for solid cancers at Rigshospitalet, Denmark in 2010‐2016 were included. Incidence rate ratios (IRR) of all‐cause, infectious and cardiovascular mortality, and ICU admissions after FN were analyzed by Poisson regression. Risk factors at the time of FN were analyzed in the subpopulation of patients with FN; all‐cause mortality was further stratified by the time periods 0‐30, 31‐365, and 366+ days after FN. We included 9018 patients with gastric (14.4%) and breast (13.1%) cancer being the most common, 51.2% had locally advanced or disseminated disease and the patients had a median Charlson Comorbidity Index score of 0 (interquartile range, 0‐0). During follow‐up, 845 (9.4%) experienced FN and 4483 (49.7%) died during 18 775 person‐years of follow‐up. After adjustment, FN was associated with increased risk of all‐cause mortality, infectious mortality, and ICU admissions with IRRs of 1.39 (95% CI, 1.24‐1.56), 1.94 (95% CI, 1.43‐2.62), and 2.28 (95% CI, 1.60‐3.24). Among those with FN, having a positive blood culture and low lymphocytes were associated with excess risk of death and ICU admissions (predominantly the first 30 days after FN), while elevated C‐reactive protein and low hemoglobin predicted mortality the first year after FN. The risk of death varied according to the time since FN; adjusted IRR per additional risk factor present for the time periods 0‐30, 31‐365, and 366+ days after FN were 2.00 (95% CI, 1.45‐2.75), 1.36 (95% CI, 1.17‐1.57), and 1.17 (95% CI, 0.98‐1.41). FN was associated with increased mortality and risk of ICU admissions. An objectively identifiable subgroup of patients among those with FN carried this excess risk.
- 6 March 2019
- Published by Wiley in International Journal of Cancer
- Vol. 146 (2) , 321-328
Development and validation of a cycle‐specific risk score for febrile neutropenia during chemotherapy cycles 2–6 in patients with solid cancers: The CSRFENCE score
The absolute risk reduction by prophylaxis in chemotherapy‐induced febrile neutropenia (FN) is largest in patients at highest underlying risk. Therefore, reliable predictive models are needed. Here, we develop and validate such a model for risk of FN during chemotherapy cycles 2–6. A prediction score for risk of FN during the first cycle has recently been published. Patients with solid cancers initiating first‐line chemotherapy in 2010–2016 were included. Cycle‐specific risk factors were assessed by Poisson regression using generalized estimating equations and random split sampling. The derivation cohort included 4,590 patients treated with 15,419 cycles, wherein 326 (2.1%) FN events occurred. Predictors of FN in multivariable analyses were: higher predicted risk of FN in the first cycle, platinum‐ or taxane‐containing therapies, concurrent radiotherapy, treatment in cycle 2 compared to later cycles, previous FN or neutropenia and not receiving granulocyte colony‐stimulating factors. Each predictor added between −2 and 8 points to each patient's score (median score 4; interquartile range, 1–6). The incidence rate ratios for developing FN in the intermediate (score 1–4), high (score 5–6) and very high risk groups (score ≥7) were 7.8 (95% CI, 2.4–24.9), 18.6 (95% CI, 5.9–58.8) and 51.7 (95% CI, 16.5–162.3) compared to the low risk group (score ≤0), respectively. The score had good discriminatory ability with a Harrell's C‐statistic of 0.78 (95% CI, 0.76–0.80) in the derivation and 0.75 (95% CI, 0.72–0.78) in the validation cohort (patient n = 2,295, cycle n = 7,670). The Cycle‐Specific Risk of FEbrile Neutropenia after ChEmotherapy score is the first published method to estimate cycle‐specific risk of FN.
- 6 March 2019
- Published by Wiley in International Journal of Cancer
- Vol. 146 (2) , 321-328
Development and validation of a cycle‐specific risk score for febrile neutropenia during chemotherapy cycles 2–6 in patients with solid cancers: The CSRFENCE score
The absolute risk reduction by prophylaxis in chemotherapy‐induced febrile neutropenia (FN) is largest in patients at highest underlying risk. Therefore, reliable predictive models are needed. Here, we develop and validate such a model for risk of FN during chemotherapy cycles 2–6. A prediction score for risk of FN during the first cycle has recently been published. Patients with solid cancers initiating first‐line chemotherapy in 2010–2016 were included. Cycle‐specific risk factors were assessed by Poisson regression using generalized estimating equations and random split sampling. The derivation cohort included 4,590 patients treated with 15,419 cycles, wherein 326 (2.1%) FN events occurred. Predictors of FN in multivariable analyses were: higher predicted risk of FN in the first cycle, platinum‐ or taxane‐containing therapies, concurrent radiotherapy, treatment in cycle 2 compared to later cycles, previous FN or neutropenia and not receiving granulocyte colony‐stimulating factors. Each predictor added between −2 and 8 points to each patient's score (median score 4; interquartile range, 1–6). The incidence rate ratios for developing FN in the intermediate (score 1–4), high (score 5–6) and very high risk groups (score ≥7) were 7.8 (95% CI, 2.4–24.9), 18.6 (95% CI, 5.9–58.8) and 51.7 (95% CI, 16.5–162.3) compared to the low risk group (score ≤0), respectively. The score had good discriminatory ability with a Harrell's C‐statistic of 0.78 (95% CI, 0.76–0.80) in the derivation and 0.75 (95% CI, 0.72–0.78) in the validation cohort (patient n = 2,295, cycle n = 7,670). The Cycle‐Specific Risk of FEbrile Neutropenia after ChEmotherapy score is the first published method to estimate cycle‐specific risk of FN.
- Open Access
- 1 October 2018
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 2 (4) , pky053
Development and Validation of a Risk Score for Febrile Neutropenia After Chemotherapy in Patients With Cancer: The FENCE Score
Febrile neutropenia (FN) after chemotherapy causes a high burden of morbidity and mortality. We aimed to develop and validate a risk score to predict FN in the first cycle of chemotherapy. We included patients with solid cancers and diffuse large B-cell lymphomas at Rigshospitalet, University of Copenhagen, 2010-2016. Predictors of FN were analyzed using Poisson regression and random split-sampling. Among 6294 patients in the derivation cohort, 360 developed FN. Female sex, older age, cancer type, disease stage, low albumin, elevated bilirubin, low creatinine clearance, infection before chemotherapy, and number of and type of chemotherapy drugs predicted FN. Compared with those at low risk (n = 2520, 40.0%), the incidence rate ratio of developing FN was 4.8 (95% confidence interval [CI] = 2.9 to 8.1), 8.7 (95% CI = 5.3 to 14.1) and 24.0 (95% CI = 15.2 to 38.0) in the intermediate (n = 1294, 20.6%), high (n = 1249, 19.8%) and very high (n = 1231, 19.6%) risk groups, respectively, corresponding to a number needed to treat with granulocyte colony-stimulating factors to avoid one FN event in the first cycle of 284, 60, 34 and 14. The discriminatory ability (Harrell’s C-statistic = 0.80, 95% CI = 0.78 to 0.82) was similar in the validation cohort (n = 3163) (0.79, 95% CI = 0.75 to 0.82). We developed and internally validated a risk score for FN in the first cycle of chemotherapy. The FENCE score is available online and provides good differentiation of risk groups.
- 1 October 2018
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 2 (4) , pky053
Open AccessDevelopment and Validation of a Risk Score for Febrile Neutropenia After Chemotherapy in Patients With Cancer: The FENCE Score
Febrile neutropenia (FN) after chemotherapy causes a high burden of morbidity and mortality. We aimed to develop and validate a risk score to predict FN in the first cycle of chemotherapy. We included patients with solid cancers and diffuse large B-cell lymphomas at Rigshospitalet, University of Copenhagen, 2010-2016. Predictors of FN were analyzed using Poisson regression and random split-sampling. Among 6294 patients in the derivation cohort, 360 developed FN. Female sex, older age, cancer type, disease stage, low albumin, elevated bilirubin, low creatinine clearance, infection before chemotherapy, and number of and type of chemotherapy drugs predicted FN. Compared with those at low risk (n = 2520, 40.0%), the incidence rate ratio of developing FN was 4.8 (95% confidence interval [CI] = 2.9 to 8.1), 8.7 (95% CI = 5.3 to 14.1) and 24.0 (95% CI = 15.2 to 38.0) in the intermediate (n = 1294, 20.6%), high (n = 1249, 19.8%) and very high (n = 1231, 19.6%) risk groups, respectively, corresponding to a number needed to treat with granulocyte colony-stimulating factors to avoid one FN event in the first cycle of 284, 60, 34 and 14. The discriminatory ability (Harrell’s C-statistic = 0.80, 95% CI = 0.78 to 0.82) was similar in the validation cohort (n = 3163) (0.79, 95% CI = 0.75 to 0.82). We developed and internally validated a risk score for FN in the first cycle of chemotherapy. The FENCE score is available online and provides good differentiation of risk groups.
- Open Access
- 4 October 2017
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 4 (suppl_1) , S700
Prediction of Febrile Neutropenia after Chemotherapy Based on Pretreatment Risk Factors among Cancer Patients
Febrile neutropenia (FN) is a common complication to chemotherapy associated with a high burden of morbidity and mortality. Reliable prediction of individual risk based on pretreatment risk factors allows for stratification of preventive interventions. We aimed to develop such a risk stratification model to predict FN in the 30 days after initiation of chemotherapy. We included consecutive treatment-naïve patients with solid cancers and diffuse large B-cell lymphomas at Copenhagen University Hospital, 2010–2015. Data were obtained from the PERSIMUNE repository of electronic health records. FN was defined as neutrophils ≤0.5 × 10E9/L at the time of either a blood culture sample or death. Time from initiation of chemotherapy to FN was analyzed using Fine-Gray models with death as a competing event. Risk factors investigated were: age, sex, body surface area, haemoglobin, albumin, neutrophil-to-lymphocyte ratio, Charlson Comorbidity Index (CCI) and chemotherapy drugs. Parameter estimates were scaled and summed to create the risk score. The scores were grouped into four: low, intermediate, high and very high risk. Among 8,585 patients, 467 experienced FN, incidence rate/30 person-days 0.05 (95% CI, 0.05–0.06). Age (1 point if > 65 years), albumin (1 point if < 39 g/L), CCI (1 point if > 2) and chemotherapy (range -5 to 6 points/drug) predicted FN. Median score at inclusion was 2 points (range –5 to 9). The cumulative incidence and the incidence rates and hazard ratios of FN are shown in Figure 1 and Table 1, respectively. We developed a risk score to predict FN the first month after initiation of chemotherapy. The score is easy to use and provides good differentiation of risk groups; the score needs independent validation before routine use. All authors: No reported disclosures.
- 4 October 2017
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 4 (suppl_1) , S700
Open AccessPrediction of Febrile Neutropenia after Chemotherapy Based on Pretreatment Risk Factors among Cancer Patients
Febrile neutropenia (FN) is a common complication to chemotherapy associated with a high burden of morbidity and mortality. Reliable prediction of individual risk based on pretreatment risk factors allows for stratification of preventive interventions. We aimed to develop such a risk stratification model to predict FN in the 30 days after initiation of chemotherapy. We included consecutive treatment-naïve patients with solid cancers and diffuse large B-cell lymphomas at Copenhagen University Hospital, 2010–2015. Data were obtained from the PERSIMUNE repository of electronic health records. FN was defined as neutrophils ≤0.5 × 10E9/L at the time of either a blood culture sample or death. Time from initiation of chemotherapy to FN was analyzed using Fine-Gray models with death as a competing event. Risk factors investigated were: age, sex, body surface area, haemoglobin, albumin, neutrophil-to-lymphocyte ratio, Charlson Comorbidity Index (CCI) and chemotherapy drugs. Parameter estimates were scaled and summed to create the risk score. The scores were grouped into four: low, intermediate, high and very high risk. Among 8,585 patients, 467 experienced FN, incidence rate/30 person-days 0.05 (95% CI, 0.05–0.06). Age (1 point if > 65 years), albumin (1 point if < 39 g/L), CCI (1 point if > 2) and chemotherapy (range -5 to 6 points/drug) predicted FN. Median score at inclusion was 2 points (range –5 to 9). The cumulative incidence and the incidence rates and hazard ratios of FN are shown in Figure 1 and Table 1, respectively. We developed a risk score to predict FN the first month after initiation of chemotherapy. The score is easy to use and provides good differentiation of risk groups; the score needs independent validation before routine use. All authors: No reported disclosures.
- Open Access
- 4 October 2017
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 4 (suppl_1) , S704
Febrile Neutropenia as a Marker of an Infectious Phenotype and Poor Long-Term Outcomes Among Patients Treated with Chemotherapy for Malignant Diseases
Febrile neutropenia (FN) is a common complication of chemotherapy, associated with increased short-term morbidity and mortality. The long-term consequences of FN are poorly elucidated. We aimed to examine whether FN identifies individuals with an infectious phenotype and poor long-term outcomes. We included patients >16 years of age, initiating first-line chemotherapy for malignant diseases at Copenhagen University Hospital, 2010–2015. Data were obtained from electronic health records. Patients were followed from the date 180 days after initiation of chemotherapy (i.e., baseline). We compared risk of infection between patients with 1 or >1 episodes of FN vs. those without FN after chemotherapy (within the period 180 days before baseline). Collection of a blood culture was used as a proxy for infection. Risk of infection was assessed using competing risks regression analysis with death or new treatment with chemotherapy as competing events. Relative risks of infection and death were estimated using Poisson regression analysis adjusted for age, sex, diagnosis, calendar year and baseline leucocyte count, with infection included as a time-updated variable in risk-analyses of death. We followed 7,210 patients with 29 types of cancers for a total of 8,523 person-years; 3,666 (51%) were women and median age was 64 years (IQR, 54–71). There were 1,373 infectious events, with incidence rates of 15.3 (95% CI, 14.4–16.2), 24.3 (95% CI, 20.7–28.5) and 26.7 (95% CI, 19.2–37.2) per 100 person-years for those with no, 1 or >1 FN episode, respectively; The adjusted incidence rate ratios were 1.80 (95% CI, 1.56–2.07) and 1.95 (95% CI, 1.43–2.65) for patients with 1 or >1 episode of FN compared with those with no FN episodes. The risk of death was increased up to 6 months after an infection; adjusted mortality rate ratios were 7.65 (95% CI, 6.79–8.62) the first month, 4.21 (95% CI, 3.76–4.70) 1–3 months after, 2.26 (95% CI, 1.58–3.24) 3–6 months after and 1.02 (95% CI, 0.87–1.21) > 6 months after an infection, compared with the time before infection. FN following chemotherapy is associated with long-term increased risk of infection. An infectious event is associated with increased mortality, persisting up to 6 months after the infection. All authors: No reported disclosures.
- 4 October 2017
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 4 (suppl_1) , S704
Open AccessFebrile Neutropenia as a Marker of an Infectious Phenotype and Poor Long-Term Outcomes Among Patients Treated with Chemotherapy for Malignant Diseases
Febrile neutropenia (FN) is a common complication of chemotherapy, associated with increased short-term morbidity and mortality. The long-term consequences of FN are poorly elucidated. We aimed to examine whether FN identifies individuals with an infectious phenotype and poor long-term outcomes. We included patients >16 years of age, initiating first-line chemotherapy for malignant diseases at Copenhagen University Hospital, 2010–2015. Data were obtained from electronic health records. Patients were followed from the date 180 days after initiation of chemotherapy (i.e., baseline). We compared risk of infection between patients with 1 or >1 episodes of FN vs. those without FN after chemotherapy (within the period 180 days before baseline). Collection of a blood culture was used as a proxy for infection. Risk of infection was assessed using competing risks regression analysis with death or new treatment with chemotherapy as competing events. Relative risks of infection and death were estimated using Poisson regression analysis adjusted for age, sex, diagnosis, calendar year and baseline leucocyte count, with infection included as a time-updated variable in risk-analyses of death. We followed 7,210 patients with 29 types of cancers for a total of 8,523 person-years; 3,666 (51%) were women and median age was 64 years (IQR, 54–71). There were 1,373 infectious events, with incidence rates of 15.3 (95% CI, 14.4–16.2), 24.3 (95% CI, 20.7–28.5) and 26.7 (95% CI, 19.2–37.2) per 100 person-years for those with no, 1 or >1 FN episode, respectively; The adjusted incidence rate ratios were 1.80 (95% CI, 1.56–2.07) and 1.95 (95% CI, 1.43–2.65) for patients with 1 or >1 episode of FN compared with those with no FN episodes. The risk of death was increased up to 6 months after an infection; adjusted mortality rate ratios were 7.65 (95% CI, 6.79–8.62) the first month, 4.21 (95% CI, 3.76–4.70) 1–3 months after, 2.26 (95% CI, 1.58–3.24) 3–6 months after and 1.02 (95% CI, 0.87–1.21) > 6 months after an infection, compared with the time before infection. FN following chemotherapy is associated with long-term increased risk of infection. An infectious event is associated with increased mortality, persisting up to 6 months after the infection. All authors: No reported disclosures.
- Open Access
- 1 May 2017
- Published by SAGE Publications in Journal of Orthopaedic Surgery
- Vol. 25 (2)
Mortality and health-related quality of life in patients surgically treated for spondylodiscitis
To assess mortality, disability, and health-related quality of life (HRQL) in patients surgically treated for spondylodiscitis. A retrospective longitudinal study was conducted on all patients surgically treated for spondylodiscitis over a 6-year period at a single tertiary spine center. Indications for surgery, pre- and postoperative neurological impairment, comorbidities, and mortality were recorded. A survey was conducted on all eligible patients with the EuroQol 5-dimension (EQ-5D) questionnaire and Oswestry Disability Index (ODI). Sixty-five patients were diagnosed with spondylodiscitis not related to recent spine surgery. One-year mortality rate was 6%. In all, 36% and 27% had pre- and postoperative neurological impairment, respectively, with only one patient experiencing deterioration postoperatively. At final follow-up (median 2 years), mean ODI was 31% (SD = 22) and mean EQ-5D time trade-off score was 0.639 (SD = 0.262); this was significantly lower than that in the normal population (p < 0.001). Patients with neurological impairment prior to index surgery had lower EQ-5D scores (p = 0.005) and higher ODI (p = 0.02) at final follow-up compared with patients without neurological impairment. Several years after surgery, patients surgically treated for spondylodiscitis have significantly lower HRQL and more disability than the background population. Neurological impairment prior to index surgery predicts adverse outcome in terms of disability and lower HRQL.
- 1 May 2017
- Published by SAGE Publications in Journal of Orthopaedic Surgery
- Vol. 25 (2)
Open AccessMortality and health-related quality of life in patients surgically treated for spondylodiscitis
To assess mortality, disability, and health-related quality of life (HRQL) in patients surgically treated for spondylodiscitis. A retrospective longitudinal study was conducted on all patients surgically treated for spondylodiscitis over a 6-year period at a single tertiary spine center. Indications for surgery, pre- and postoperative neurological impairment, comorbidities, and mortality were recorded. A survey was conducted on all eligible patients with the EuroQol 5-dimension (EQ-5D) questionnaire and Oswestry Disability Index (ODI). Sixty-five patients were diagnosed with spondylodiscitis not related to recent spine surgery. One-year mortality rate was 6%. In all, 36% and 27% had pre- and postoperative neurological impairment, respectively, with only one patient experiencing deterioration postoperatively. At final follow-up (median 2 years), mean ODI was 31% (SD = 22) and mean EQ-5D time trade-off score was 0.639 (SD = 0.262); this was significantly lower than that in the normal population (p < 0.001). Patients with neurological impairment prior to index surgery had lower EQ-5D scores (p = 0.005) and higher ODI (p = 0.02) at final follow-up compared with patients without neurological impairment. Several years after surgery, patients surgically treated for spondylodiscitis have significantly lower HRQL and more disability than the background population. Neurological impairment prior to index surgery predicts adverse outcome in terms of disability and lower HRQL.
- 20 October 2015
- Published by Taylor & Francis in Infectious Diseases
- Vol. 48 (3) , 201-208
Long-term prognosis and causes of death after spondylodiscitis: A Danish nationwide cohort study
Background: Data on long-term prognosis after spondylodiscitis are scarce. The purpose of this study was to determine long-term mortality and the causes of death after spondylodiscitis. Methods: A nationwide, population-based cohort study using national registries of patients diagnosed with non-post-operative pyogenic spondylodiscitis from 1994–2009, alive 1 year after diagnosis (n = 1505). A comparison cohort from the background population individually matched for sex and age was identified (n = 7525). Kaplan-Meier survival curves were constructed and Poisson regression analyses used to estimate mortality rate ratios (MRR). Results: Three hundred and sixty-five patients (24%) and 1115 individuals from the comparison cohort (15%) died. Unadjusted MRR for spondylodiscitis patients was 1.76 (95% CI = 1.57–1.98) and 1.47 (95% CI = 1.30–1.66) after adjustment for comorbidity. No deaths were observed in 128 patients under the age of 16 years. Siblings of patients did not have increased long-term mortality compared with siblings of the individuals from the comparison cohort. This study observed increased mortality due to infections (MRR = 2.57), neoplasms (MRR = 1.40), endocrine (MRR = 3.72), cardiovascular (MRR = 1.62), respiratory (MRR = 1.71), gastrointestinal (MRR = 3.35), musculoskeletal (MRR = 5.39) and genitourinary diseases (MRR = 3.37), but also due to trauma, poisoning and external causes (MRR = 2.78), alcohol abuse-related diseases (MRR = 5.59) and drug abuse-related diseases (6 vs 0 deaths, MRR not calculable). Conclusions: Patients diagnosed with spondylodiscitis have increased long-term mortality, mainly due to comorbidities, particularly substance abuse.
- 20 October 2015
- Published by Taylor & Francis in Infectious Diseases
- Vol. 48 (3) , 201-208
Long-term prognosis and causes of death after spondylodiscitis: A Danish nationwide cohort study
Background: Data on long-term prognosis after spondylodiscitis are scarce. The purpose of this study was to determine long-term mortality and the causes of death after spondylodiscitis. Methods: A nationwide, population-based cohort study using national registries of patients diagnosed with non-post-operative pyogenic spondylodiscitis from 1994–2009, alive 1 year after diagnosis (n = 1505). A comparison cohort from the background population individually matched for sex and age was identified (n = 7525). Kaplan-Meier survival curves were constructed and Poisson regression analyses used to estimate mortality rate ratios (MRR). Results: Three hundred and sixty-five patients (24%) and 1115 individuals from the comparison cohort (15%) died. Unadjusted MRR for spondylodiscitis patients was 1.76 (95% CI = 1.57–1.98) and 1.47 (95% CI = 1.30–1.66) after adjustment for comorbidity. No deaths were observed in 128 patients under the age of 16 years. Siblings of patients did not have increased long-term mortality compared with siblings of the individuals from the comparison cohort. This study observed increased mortality due to infections (MRR = 2.57), neoplasms (MRR = 1.40), endocrine (MRR = 3.72), cardiovascular (MRR = 1.62), respiratory (MRR = 1.71), gastrointestinal (MRR = 3.35), musculoskeletal (MRR = 5.39) and genitourinary diseases (MRR = 3.37), but also due to trauma, poisoning and external causes (MRR = 2.78), alcohol abuse-related diseases (MRR = 5.59) and drug abuse-related diseases (6 vs 0 deaths, MRR not calculable). Conclusions: Patients diagnosed with spondylodiscitis have increased long-term mortality, mainly due to comorbidities, particularly substance abuse.
- 1 September 2014
- Published by Elsevier in Journal of Infection
- Vol. 69 (3) , 252-258
Long-term mortality after Staphylococcus aureus spondylodiscitis: A Danish nationwide population-based cohort study
- 1 September 2014
- Published by Elsevier in Journal of Infection
- Vol. 69 (3) , 252-258
Long-term mortality after Staphylococcus aureus spondylodiscitis: A Danish nationwide population-based cohort study
- 21 December 2012
- Published by Taylor & Francis in Scandinavian Journal of Infectious Diseases
- Vol. 45 (6) , 417-424
Microbiological and therapeutic challenges in infectious spondylodiscitis: a cohort study of 100 cases, 2006–2011
Background: The microbiological diagnosis of infectious spondylodiscitis is often difficult to establish and the disease requires prolonged antibiotic treatment. We analyzed the medical records of 100 patients admitted for infectious spondylodiscitis from 2006 to 2011 with an emphasis on (1) the diagnostic utility of blood cultures and invasive biopsies in the microbiological diagnosis, (2) clinical features differentiating Staphylococcus aureus infections from those with other aetiologies, and (3) evaluation of the outcome of the antimicrobial therapy. Methods: A retrospective chart review was performed. Results: Patients were diagnosed a median of 32 days after symptom onset and treated for a median of 91 days; 68% had abscesses, 65% experienced sequelae, and the 1-y crude mortality was 11%. Blood cultures yielded a diagnosis in 67%. Among blood culture-positive cases, no other culture or polymerase chain reaction results yielded further diagnoses. S. aureus infections comprised 58%. These cases compared to those with other aetiologies were younger, more frequently female, had a higher C-reactive protein, and more often had neutrocytosis, bacteraemia, and abscess formation. Presumed side effects mediated a change in treatment 33 times in 23 patients. Four patients experienced relapse. Conclusions: This contemporary case-series on infectious spondylodiscitis mostly concurs with previous studies. We emphasize the importance of thorough blood culture sampling before more invasive tests are considered. S. aureus infections exhibit, in particular, prominent pyogenic characteristics. Prospective studies evaluating the choice and duration of antimicrobial treatment are needed.
- 21 December 2012
- Published by Taylor & Francis in Scandinavian Journal of Infectious Diseases
- Vol. 45 (6) , 417-424
Microbiological and therapeutic challenges in infectious spondylodiscitis: a cohort study of 100 cases, 2006–2011
Background: The microbiological diagnosis of infectious spondylodiscitis is often difficult to establish and the disease requires prolonged antibiotic treatment. We analyzed the medical records of 100 patients admitted for infectious spondylodiscitis from 2006 to 2011 with an emphasis on (1) the diagnostic utility of blood cultures and invasive biopsies in the microbiological diagnosis, (2) clinical features differentiating Staphylococcus aureus infections from those with other aetiologies, and (3) evaluation of the outcome of the antimicrobial therapy. Methods: A retrospective chart review was performed. Results: Patients were diagnosed a median of 32 days after symptom onset and treated for a median of 91 days; 68% had abscesses, 65% experienced sequelae, and the 1-y crude mortality was 11%. Blood cultures yielded a diagnosis in 67%. Among blood culture-positive cases, no other culture or polymerase chain reaction results yielded further diagnoses. S. aureus infections comprised 58%. These cases compared to those with other aetiologies were younger, more frequently female, had a higher C-reactive protein, and more often had neutrocytosis, bacteraemia, and abscess formation. Presumed side effects mediated a change in treatment 33 times in 23 patients. Four patients experienced relapse. Conclusions: This contemporary case-series on infectious spondylodiscitis mostly concurs with previous studies. We emphasize the importance of thorough blood culture sampling before more invasive tests are considered. S. aureus infections exhibit, in particular, prominent pyogenic characteristics. Prospective studies evaluating the choice and duration of antimicrobial treatment are needed.
- Open Access
- 1 January 2012
- Published by Springer Nature in Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine
- Vol. 20 (1) , 16
Effect of feedback on delaying deterioration in quality of compressions during 2 minutes of continuous chest compressions: a randomized manikin study investigating performance with and without feedback
Good quality basic life support (BLS) improves outcome following cardiac arrest. As BLS performance deteriorates over time we performed a parallel group, superiority study to investigate the effect of feedback on quality of chest compression with the hypothesis that feedback delays deterioration of quality of compressions.
- 1 January 2012
- Published by Springer Nature in Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine
- Vol. 20 (1) , 16
Open AccessEffect of feedback on delaying deterioration in quality of compressions during 2 minutes of continuous chest compressions: a randomized manikin study investigating performance with and without feedback
Good quality basic life support (BLS) improves outcome following cardiac arrest. As BLS performance deteriorates over time we performed a parallel group, superiority study to investigate the effect of feedback on quality of chest compression with the hypothesis that feedback delays deterioration of quality of compressions.